Literature DB >> 2989936

Infectious-inflammatory changes in cyclic AMP levels and in their regulation by prostaglandins in human peritoneal macrophages.

M J Adolfs, M W Fieren, I L Bonta.   

Abstract

Peritoneal macrophages of renal patients on continuous ambulatory peritoneal dialysis (CAPD) have been collected when CAPD was without complications, during an intercurrent infectious peritoneal inflammation and after recovery. Levels of cyclic AMP, release of cyclo-oxygenase metabolites, and responsiveness, in terms of cyclic AMP elevation, to either PGE2 or to DC-PGI2 (a stable analogue of PGI2) were examined. Peritoneal inflammation was associated with a sharp drop in cyclic AMP, which was restored after recovery. Production of TXA2, PGI2 and PGE2 parallelled the direction of changes in cyclic AMP levels, except, that release of PGE2 entirely failed to recover. Macrophages during the uncomplicated stage of CAPD proved more responsive to DC-PGI2 than to PGE2. During inflammation the cells displayed a marked increase in sensitivity towards PG stimulation. Improved sensitivity was more pronounced with PGE2 than with DC-PGI2 and so the original difference between responsiveness of the cells to the PGs was abolished. Several findings are compatible with the view that endogenous PGI2 governs the cyclic AMP levels in human non-inflammatory peritoneal macrophages. However, during infectious-inflammation the cells undergo changes which render a reduced production of PGI2 insufficient to explain the drop in cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989936     DOI: 10.1016/0262-1746(85)90021-6

Source DB:  PubMed          Journal:  Prostaglandins Leukot Med        ISSN: 0262-1746


  7 in total

1.  PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion.

Authors:  M J Adolfs; F D Beusenberg; I L Bonta
Journal:  Agents Actions       Date:  1989-01

2.  Regulation of cyclic AMP levels in alveolar macrophages of guinea pigs and man by prostanoids and beta-adrenergic agents.

Authors:  F D Beusenberg; M J Adolfs; J M van Schaik-van Groningen; H C Hoogsteden; I L Bonta
Journal:  Agents Actions       Date:  1989-01

3.  Increased in vitro release of interleukin-1 by LPS stimulated peritoneal macrophages obtained from patients on continuous ambulatory peritoneal dialysis (CAPD) during an infectious peritonitis.

Authors:  M W Fieren; G J van den Bemd; I L Bonta
Journal:  Agents Actions       Date:  1990-01

4.  Human peritoneal macrophages: clinical models of inflammation and potential targets of antiinflammatory drugs.

Authors:  J H Wilson; I L Bonta
Journal:  Agents Actions       Date:  1986-01

5.  Down-regulation of cyclooxygenase product generation by human peritoneal macrophages.

Authors:  R Mackenzie; G A Coles; N Topley; W S Powell; J D Williams
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

6.  Inflammation amplifies the antitumor cytostasis by human peritoneal macrophages.

Authors:  S Ben-Efraim; C Tak; M J Fieren; G J Van den Bemd; I L Bonta
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

7.  Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.